Eisenmenger syndrome

Definition

• Severe pulmonary arterial hypertension (PAH) resulting in right-to-left shunting at atrial, ventricular, or pulmonary arterial levels.
• Represents extreme end-stage of uncorrected congenital heart disease (CHD) with systemic-to-pulmonary shunts.
• Defined hemodynamically by pulmonary vascular resistance (PVR) >12 Wood units or PVR/systemic vascular resistance (SVR) ratio $\ge$ 1.0.
• Shunt becomes bidirectional or completely right-to-left, with Qp/Qs ratio approximating 1.0 (typically 0.8–1.2).

Pathophysiology

• Initial large left-to-right shunt causes increased pulmonary blood flow (hyperkinetic PH).
• Chronic volume and pressure overload (shear stress) on pulmonary arterioles induces endothelial dysfunction.
• Progressive vascular remodeling leads to irreversible obstructive pathologic changes.
• Right ventricle (RV) undergoes homeometric adaptation (hypertrophy) to match rising pulmonary pressures, preserving RV function for decades.

Heath-Edwards Classification of Pulmonary Vascular Disease

Grade	Histologic Characteristics	Reversibility
Grade I	Medial hypertrophy alone	Reversible.
Grade II	Medial hypertrophy + intimal hyperplasia	Reversible.
Grade III	Near-obliteration of vessel lumen	Reversible/Borderline.
Grade IV	Arterial dilation	Irreversible.
Grade V	Plexiform lesions and angiomatoid formation	Irreversible.
Grade VI	Fibrinoid necrosis	Irreversible.

Etiology & Risk Factors

• Rapidity of progression depends on shunt location, size, and genetic factors.
• Down Syndrome: High predisposition to early, rapid progression of pulmonary vascular disease (PVD).

Shunt Type	Anatomy	Pathophysiology	Clinical Course
Post-Tricuspid	VSD, PDA, Aortopulmonary window	Exposes pulmonary circulation to both volume and pressure overload.	Early onset of PVD (often first years of life).
Pre-Tricuspid	ASD (Secundum, Sinus Venosus)	Exposes pulmonary circulation to volume overload only.	Late onset. Rare progression to ES (“Eisenmenger ASD”) requiring genetic predisposition.

Clinical Features

Symptoms

• Effort intolerance, dyspnea, fatigue, and palpitations.
• Syncope or near-syncope (due to inability to increase cardiac output).
• Angina or atypical chest pain.

Physical Signs

• Central cyanosis and digital clubbing.
• Differential Cyanosis: Seen in PDA with reversed shunt. Pink upper body (brain/arms receive saturated blood) and cyanotic lower body (desaturated blood enters descending aorta).
• Right ventricular heave and palpable pulmonary artery pulsation.

Auscultation

• S2: Loud, narrowly split or single S2 (accentuated pulmonary component).
• Shunt Murmur: Typically absent (pressures between chambers equalize).
• Tricuspid Regurgitation (TR): Holosystolic murmur at left lower sternal border.
• Pulmonary Insufficiency (PI): Early decrescendo diastolic murmur (Graham-Steell murmur).
• Gallop: Right-sided S3 or S4 gallop in decompensated states.

Multisystemic Complications

System	Complications & Pathogenesis	Management Nuances
Hematologic	Secondary erythrocytosis (adaptive response to hypoxia). Increased risk of hyperviscosity.	Treat underlying iron deficiency. Avoid routine phlebotomy.
Hemostatic	Thrombocytopenia (megakaryocytes bypass lungs), platelet dysfunction, bleeding diathesis.	Avoid routine anticoagulation unless specific indications (PA thrombosis, AF) due to bleeding risk.
Pulmonary	Massive PA dilation causing left main coronary compression, PA in-situ thrombosis, hemoptysis (rupture of plexiform lesions).	Hemoptysis can be life-threatening. Reverse anticoagulation, consider selective lung intubation.
Neurologic	Paradoxical emboli causing TIA/Stroke, brain abscess.	Strict IV line care (filters) to prevent air/paradoxical emboli.
Renal/Metabolic	Renal dysfunction (glomerulopathy from hyperviscosity), Hyperuricemia (Gout), Cholelithiasis.	Cautious use of diuretics. Monitor renal function.
Obstetric	Pregnancy is strictly contraindicated (mWHO class 4). Maternal mortality 16-50%.	Contraception mandatory. Avoid estrogen. IUD or subdermal devices preferred.

Investigations

Electrocardiogram (ECG)

• Right ventricular hypertrophy (RVH).
• Right axis deviation or extreme axis (in AV septal defects).
• Right atrial or biatrial enlargement.
• QRS duration >110 ms and resting HR >90 bpm indicate higher mortality risk.

Chest Radiograph (CXR)

• Prominent central pulmonary arteries with rapid tapering (peripheral pruning).
• RV enlargement.
• Calcification in PDA location (between descending aorta and left PA) or within dilated central PAs.

Echocardiography

• Essential for defining cardiac defect anatomy and RV function.
• Demonstrates right-to-left or bidirectional shunting.
• Prognostic markers: Tricuspid annular plane systolic excursion (TAPSE), RA area, RV strain.

Cardiac Magnetic Resonance (CMR) & CT

• CMR evaluates RV volumes, function, and establishes that pulmonary flow is not significantly raised (confirming PVD).
• CT identifies PA in-situ thrombosis, PA calcification, and coronary compression.

Cardiac Catheterization & CPET

• Determines vasoreactivity to identify potential responders to therapy.
• Cardiopulmonary Exercise Testing (CPET): Shows extremely low peak VO2 (<50% predicted), high VE/VCO2 slope (inefficient ventilation), and chronotropic incompetence.

Management

1. General & Supportive Measures

• Contraindication to Closure: Surgical or device closure of the defect is strictly contraindicated and leads to adverse outcomes.
• Iron Supplementation: Iron deficiency (indicated by low ferritin/transferrin saturation, not MCV) worsens symptoms. Oral/IV iron improves exercise capacity and quality of life.
• Hydration: Avoid dehydration to prevent hyperviscosity.
• Oxygen: Continuous oxygen lacks proven long-term survival benefit but may provide symptomatic relief in select cases.
• Endocarditis Prophylaxis: Indicated prior to high-risk dental procedures.

2. PAH-Targeted Pharmacotherapy

• Endothelin Receptor Antagonists (ERAs): Bosentan is standard first-line therapy (proven by BREATHE-5 trial to improve 6-minute walk distance and lower PVR without worsening systemic desaturation).
• Phosphodiesterase-5 (PDE-5) Inhibitors: Sildenafil or tadalafil indicated for symptomatic patients.
• Prostanoids: Epoprostenol or treprostinil utilized in advanced cases.
• Combination Therapy: Combining ERAs and PDE-5 inhibitors is recommended for progressive symptoms.

3. Advanced Surgical Options

• Transplantation: Heart-lung transplantation or bilateral lung transplantation with concurrent cardiac repair remains the only definitive option for refractory, end-stage disease.